Canaccord Genuity Reiterates a 'Buy' on Amarin Corp (AMRN); Vascepa Approved, Focus Shifts to BD
Tweet Send to a FriendGet Alerts AMRN Hot Sheet
Price: $6.47 -1.97%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade AMRN Now!
Canaccord Genuity reiterates a 'Buy' on Amarin Corporation (NASDAQ: AMRN) price target of $27.00 (from $25.00).
Analyst, Ritu Baral, said, "Reiterate rating, increasing target to $27 on Vascepa approval & commercial, partnering potential. We now expect BD talks to intensify and Vascepa to receive NCE (5-year exclusivity). We have changed our valuation method from pure pNPV to a sum of the parts of a DCF of high triglyceride sales and pNPV of mixed dyslipidemia sales, which raises our target, on partial removal of regulatory risk."
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $15.32 yesterday, with a 52 week range of $5.99-$15.96.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Ritu Baral, said, "Reiterate rating, increasing target to $27 on Vascepa approval & commercial, partnering potential. We now expect BD talks to intensify and Vascepa to receive NCE (5-year exclusivity). We have changed our valuation method from pure pNPV to a sum of the parts of a DCF of high triglyceride sales and pNPV of mixed dyslipidemia sales, which raises our target, on partial removal of regulatory risk."
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $15.32 yesterday, with a 52 week range of $5.99-$15.96.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amarin (AMRN) NCE Delay Not all Negative - MKM Partners
- Goldman Sachs Upgrades Tanger Factory Outlet Centers (SKT) to Neutral
- Amarin (AMRN) Vascepa sNDA Set for Oct. 16, 2013, According to FDA
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, FDARelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
